Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Disease-modifying treatments for multiple sclerosis - a review of approved medications.
Cardiovascular Dysfunction in Multiple Sclerosis.
Does Physical Activity Change Over 24 Months in Persons With Relapsing-Remitting Multiple Sclerosis?
The Significance of Matrix Metalloproteinases in the Immunopathogenesis and Treatment of Multiple Sclerosis.
Demyelinating disease and psoriasis: Interferon versus dimethyl fumarate.
Annotation of functional variation within non-MHC MS susceptibility loci through bioinformatics analysis.
Enhanced accumulation of Kir4.1 protein, but not mRNA, in a murine model of cuprizone-induced demyelination.
Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.
Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.
Is a hypothetical melanoma-like neuromelanin the underlying factor essential for the aetiopathogenesis and clinical manifestations of multiple sclerosis?
Assessments of nursing home guidelines for quality of care provided to residents with multiple sclerosis.
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.
LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in experimental autoimmune encephalomyelitis mice.
Editorial: Fatigue in Multiple Sclerosis.
Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis.
TGF-beta1 regulates human brain pericyte inflammatory processes involved in neurovasculature function.
New evidence for teriflunomide in multiple sclerosis.
▼Teriflunomide for multiple sclerosis.
Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis.
Analysis of the host transcriptome from demyelinating spinal cord of murine coronavirus-infected mice.
1,25-dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation.
Persistent Headache in Patients With Multiple Sclerosis Starting Treatment With Fingolimod.
Novel Insights and Therapeutics in Multiple Sclerosis.
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS.
Association Between Self-Administered Expanded Disease Severity Scale (Edss) and Multiple Sclerosis Impact Scale (Msis-29): Results from The Burden of Illness In Patients With Multiple Sclerosis In Finland (Defense) Study.
Pages
« first
‹ previous
…
655
656
657
658
659
660
661
662
663
…
next ›
last »